glp-1 news 2025 october 16 Who Gets the Shot? Access by State GLP-1 Drugs: 2025 Pulse Survey

Some research even suggests that tesamorelin could increase the risk of developing diabetes [23]

Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al

Rouse and M

Unlocking the Power of Cagrilintide: A Deep Dive Into Dosage Schedules and What to Expect Deep Dive Into Dosage Schedules and What to Expect In the evolving world of weight management and metabolic health, novel peptides are reshaping how patients and researchers approach obesity, type 2 diabetes, and related conditions

Watch the full interview to hear more: This is exactly what the market needsespecially as more employers are pulling back coverage of GLP-1s

, Lu, M